DK1720571T3 - Fremgangsmåde til behandling af hæmolytisk sygdom - Google Patents

Fremgangsmåde til behandling af hæmolytisk sygdom

Info

Publication number
DK1720571T3
DK1720571T3 DK05712607.0T DK05712607T DK1720571T3 DK 1720571 T3 DK1720571 T3 DK 1720571T3 DK 05712607 T DK05712607 T DK 05712607T DK 1720571 T3 DK1720571 T3 DK 1720571T3
Authority
DK
Denmark
Prior art keywords
treatment
haemolytic disease
haemolytic
disease
Prior art date
Application number
DK05712607.0T
Other languages
Danish (da)
English (en)
Inventor
Russell P Rother
Leonard Bell
Original Assignee
Alexion Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34808492&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1720571(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Alexion Pharma Inc filed Critical Alexion Pharma Inc
Application granted granted Critical
Publication of DK1720571T3 publication Critical patent/DK1720571T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Reproductive Health (AREA)
  • Neurology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Transplantation (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK05712607.0T 2004-02-03 2005-02-03 Fremgangsmåde til behandling af hæmolytisk sygdom DK1720571T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/771,552 US20050169921A1 (en) 2004-02-03 2004-02-03 Method of treating hemolytic disease
PCT/US2005/003225 WO2005074607A2 (en) 2004-02-03 2005-02-03 Method of treating hemolytic disease

Publications (1)

Publication Number Publication Date
DK1720571T3 true DK1720571T3 (da) 2012-09-03

Family

ID=34808492

Family Applications (1)

Application Number Title Priority Date Filing Date
DK05712607.0T DK1720571T3 (da) 2004-02-03 2005-02-03 Fremgangsmåde til behandling af hæmolytisk sygdom

Country Status (16)

Country Link
US (5) US20050169921A1 (enExample)
EP (7) EP2520311A3 (enExample)
JP (5) JP2007520494A (enExample)
KR (1) KR101197799B1 (enExample)
CN (4) CN103446584A (enExample)
AU (1) AU2005209854B2 (enExample)
CA (1) CA2554632A1 (enExample)
CY (1) CY1113190T1 (enExample)
DK (1) DK1720571T3 (enExample)
ES (1) ES2389093T3 (enExample)
IL (2) IL177003A0 (enExample)
NZ (1) NZ549328A (enExample)
PL (1) PL1720571T3 (enExample)
PT (1) PT1720571E (enExample)
SI (1) SI1720571T1 (enExample)
WO (1) WO2005074607A2 (enExample)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6969601B2 (en) 1997-04-03 2005-11-29 Jensenius Jens Chr MASP-2, a complement-fixing enzyme, and uses for it
US20050271660A1 (en) * 2002-09-06 2005-12-08 Alexion Pharmaceuticals, Inc. Nebulization of monoclonal antibodies for treating pulmonary diseases
EP1545611B1 (en) * 2002-09-06 2016-11-09 Alexion Pharmaceuticals, Inc. Method of treatment of asthma using antibodies to complement component c5
US9415102B2 (en) 2002-09-06 2016-08-16 Alexion Pharmaceuticals, Inc. High concentration formulations of anti-C5 antibodies
US20070116710A1 (en) * 2004-02-03 2007-05-24 Leonard Bell Methods of treating hemolytic anemia
US20050169921A1 (en) * 2004-02-03 2005-08-04 Leonard Bell Method of treating hemolytic disease
EP3056218A1 (en) * 2004-05-14 2016-08-17 Alexion Pharmaceuticals, Inc. Prolongation of survival of an allograft by inhibiting complement activity
US8840893B2 (en) 2004-06-10 2014-09-23 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
US7919094B2 (en) * 2004-06-10 2011-04-05 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
WO2006107708A1 (en) * 2005-04-04 2006-10-12 Alexion Pharmaceuticals, Inc. Treatment of disease caused by excess free hemoglobin
ES2551202T5 (es) * 2005-11-04 2018-11-30 Genentech, Inc. Uso de inhibidores de la vía del complemento para tratar enfermedades oculares
EP1988882B1 (en) * 2006-03-02 2014-12-17 Alexion Pharmaceuticals, Inc. Prolongation of survival of an allograft by inhibiting complement activity
DK2359834T5 (en) * 2006-03-15 2017-02-06 Alexion Pharma Inc Treatment of paroxysmal nocturnal hemoglobinuria patients with a complement inhibitor
DK2006381T3 (en) 2006-03-31 2016-02-22 Chugai Pharmaceutical Co Ltd PROCEDURE FOR REGULATING ANTIBODIES BLOOD PHARMACOKINETICS
EP3028716B1 (en) 2006-10-10 2020-09-16 Regenesance B.V. Complement inhibition for improved nerve regeneration
CN106084054A (zh) * 2006-11-02 2016-11-09 健泰科生物技术公司 人源化的抗‑d因子抗体
DK2202245T3 (en) 2007-09-26 2016-11-21 Chugai Pharmaceutical Co Ltd A method of modifying an antibody isoelectric point VIA amino acid substitution in CDR
PT2708559T (pt) 2008-04-11 2018-05-16 Chugai Pharmaceutical Co Ltd Molécula de ligação ao antigénio capaz de se ligar repetidamente a duas ou mais moléculas de antigénio
CR20170001A (es) 2008-04-28 2017-08-10 Genentech Inc Anticuerpos anti factor d humanizados
WO2010015608A1 (en) 2008-08-05 2010-02-11 Novartis Ag Compositions and methods for antibodies targeting complement protein c5
RS64039B1 (sr) * 2008-11-10 2023-04-28 Alexion Pharma Inc Metode i kompozicije za lečenje poremećaja povezanih sa komplementom
CN106390117A (zh) * 2009-10-16 2017-02-15 奥默罗斯公司 通过抑制masp‑2依赖性补体活化治疗弥散性血管内凝血的方法
US20110124019A1 (en) * 2009-11-25 2011-05-26 The Charlotte-Mecklenburg Hospital Authority Method of using carbonic anhydrase to detect hemolysis
US9420770B2 (en) 2009-12-01 2016-08-23 Indiana University Research & Technology Corporation Methods of modulating thrombocytopenia and modified transgenic pigs
CN105218674A (zh) * 2010-03-11 2016-01-06 瑞纳神经科学公司 呈pH依赖性抗原结合的抗体
MX365235B (es) 2010-11-30 2019-05-28 Chugai Pharmaceutical Co Ltd Molécula de unión a antígeno capaz de unir repetidamente a la pluralidad de moléculas de antígeno.
AU2015230852B2 (en) * 2011-03-08 2017-09-14 Alexion Pharmaceuticals, Inc. High concentration antibody formulations
KR20220044616A (ko) * 2011-04-08 2022-04-08 유니버시티 오브 레스터 Ｍａｓｐ-2 의존적 보체 활성화와 관련된 질병을 치료하는 방법
US9644035B2 (en) 2011-04-08 2017-05-09 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
CA2859493A1 (en) 2011-12-21 2013-06-27 Novartis Ag Compositions and methods for antibodies targeting factor p
CN104205155A (zh) * 2012-03-16 2014-12-10 亚力克恩制药公司 给接受补体抑制剂的患者分配补体抑制药物的方法
CA3087933A1 (en) * 2012-04-06 2013-12-05 Omeros Corporation Compositions and methods of inhibiting masp-1 and/or masp-2 and/or masp-3 for the treatment of paroxysmal nocturnal hemoglobinuria
US9579360B2 (en) * 2012-06-20 2017-02-28 The Trustees Of The University Of Pennsylvania Methods of treating or preventing periodontitis and diseases associated with periodontitis
WO2014160958A1 (en) 2013-03-29 2014-10-02 Alexion Pharmaceuticals, Inc. Compositions and methods for increasing the serum half-life of a therapeutic agent targeting complement c5
AU2014306002B2 (en) 2013-08-07 2017-05-25 Alexion Pharmaceuticals, Inc. Atypical hemolytic uremic syndrome (aHUS) biomarker proteins
CR20160132A (es) 2013-08-12 2016-08-25 Genentech Inc Composiciones y método para tratar condiciones asociadas con el complemento
WO2015058143A1 (en) 2013-10-17 2015-04-23 Omeros Corporation Methods for treating conditions associated with masp-2 dependent complement activation
SG11201608868PA (en) 2014-05-01 2016-11-29 Genentech Inc Anti-factor d antibody variants and uses thereof
HUE056489T2 (hu) 2014-12-19 2022-02-28 Chugai Pharmaceutical Co Ltd Anti-C5 antitestek és alkalmazási eljárások
MX2017005774A (es) 2014-12-19 2017-07-28 Chugai Pharmaceutical Co Ltd Anticuerpos antimiostatina, polipeptidos que contienen regiones fc variantes, y metodos de uso.
JP2018511557A (ja) 2015-01-22 2018-04-26 中外製薬株式会社 ２種以上の抗ｃ５抗体の組み合わせおよび使用方法
US20190135903A1 (en) * 2015-03-31 2019-05-09 Alexion Pharmaceuticals, Inc. Identifying and treating subpopulations of paroxysmal nocturnal hemoglobinuria (pnh) patients
EP3368074A2 (en) 2015-10-30 2018-09-05 Hoffmann-La Roche AG Anti-factor d antibodies and conjugates
EP3368090A1 (en) 2015-10-30 2018-09-05 H. Hoffnabb-La Roche Ag Anti-factor d antibody variant conjugates and uses thereof
MY191668A (en) 2016-06-14 2022-07-06 Regeneron Pharma Anti-c5 antibodies and uses thereof
KR102538749B1 (ko) 2016-08-05 2023-06-01 추가이 세이야쿠 가부시키가이샤 Il-8 관련 질환의 치료용 또는 예방용 조성물
IT201600121482A1 (it) * 2016-11-30 2018-05-30 Univ Degli Studi Di Verona Fattore H per l’uso nel trattamento e/o prevenzione della formazione di eterotrombi in pazienti affetti da anemia falciforme
CN110167961A (zh) 2017-01-31 2019-08-23 中外制药株式会社 用于治疗或预防c5相关疾病的药物组合物和治疗或预防c5相关疾病的方法
JP2021506241A (ja) 2017-12-13 2021-02-22 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 抗ｃ５抗体組み合わせ物およびその使用
GB201800620D0 (en) 2018-01-15 2018-02-28 Univ Manchester C3b Binding Polypeptide
US20190247560A1 (en) 2018-02-13 2019-08-15 Gambro Lundia Ab Extracorporeal devices and methods of treating complement factor related diseases
MY210523A (en) 2018-08-01 2025-09-29 Univ Osaka A pharmaceutical composition for use in the treatment or prevention of a c5-related disease and a method for treating or preventing a c5-related disease
CN114929273A (zh) 2019-07-31 2022-08-19 豪夫迈·罗氏有限公司 通过使用抗c5抗体可伐利单抗来治疗或预防c5相关疾病的剂量和施用方案
AU2020319677A1 (en) 2019-07-31 2022-01-06 F. Hoffmann-La Roche Ag Dosage and administration regimen for the treatment or prevention of C5-related diseases by the use of the anti-C5 antibody Crovalimab

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4686100A (en) * 1985-04-02 1987-08-11 The Board Of Trustees Of The Leland Stanford Junior University Method for the treatment of adult respiratory distress syndrome
US5135916A (en) * 1989-06-12 1992-08-04 Oklahoma Medical Research Foundation Inhibition of complement mediated inflammatory response
DE3924924A1 (de) 1989-07-27 1991-02-07 Goetze Otto Verfahren zum nachweis und/oder der quantitativen bestimmung von komplementpeptid c5a und/oder c5adesarg
US6074642A (en) * 1994-05-02 2000-06-13 Alexion Pharmaceuticals, Inc. Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
US5650825A (en) * 1995-03-31 1997-07-22 Matsushita Electric Corporation Of America Method and apparatus for sending private data instead of stuffing bits in an MPEG bit stream
DE19826743A1 (de) * 1998-06-16 1999-12-23 Bayer Ag Verfahren zur Herstellung von geträgerten Polymerisationskatalysatorsystemen und Verwendung dieser zur Homo- und Copolymerisation ungesättigter Monomere
ATE320450T1 (de) * 2000-12-05 2006-04-15 Alexion Pharma Inc Rationell entworfene antikörper
WO2003081206A2 (en) * 2002-03-18 2003-10-02 Alexion Pharmaceuticals, Inc. Stratification of patient populations having or suspected of having rheumatoid arthritis
US7361339B2 (en) * 2003-01-09 2008-04-22 Alexion Pharmaceuticals, Inc. Methods for reducing morality associated with acute myocardial infarction
US20050169921A1 (en) * 2004-02-03 2005-08-04 Leonard Bell Method of treating hemolytic disease

Also Published As

Publication number Publication date
CN103446584A (zh) 2013-12-18
JP5873047B2 (ja) 2016-03-01
EP2522362A1 (en) 2012-11-14
US20100068202A1 (en) 2010-03-18
JP2017057234A (ja) 2017-03-23
PT1720571E (pt) 2012-08-29
EP1720571A2 (en) 2006-11-15
JP2013213044A (ja) 2013-10-17
KR101197799B9 (ko) 2024-02-08
EP1720571B9 (en) 2012-10-24
CN1938047A (zh) 2007-03-28
EP2522363A1 (en) 2012-11-14
PL1720571T3 (pl) 2012-11-30
US20050191298A1 (en) 2005-09-01
JP2007520494A (ja) 2007-07-26
WO2005074607A3 (en) 2006-09-14
SI1720571T1 (sl) 2012-10-30
KR20070009996A (ko) 2007-01-19
EP2522361A1 (en) 2012-11-14
HK1094950A1 (en) 2007-04-20
EP2520311A2 (en) 2012-11-07
CY1113190T1 (el) 2016-04-13
EP1720571A4 (en) 2008-11-19
CN103977402A (zh) 2014-08-13
US20120308559A1 (en) 2012-12-06
EP2522364A1 (en) 2012-11-14
WO2005074607A2 (en) 2005-08-18
EP2520311A3 (en) 2012-11-14
US20050169921A1 (en) 2005-08-04
AU2005209854A1 (en) 2005-08-18
CA2554632A1 (en) 2005-08-18
KR101197799B1 (ko) 2012-11-05
NZ549328A (en) 2010-12-24
EP1720571B1 (en) 2012-06-13
IL177003A0 (en) 2006-12-10
ES2389093T3 (es) 2012-10-23
JP2015083611A (ja) 2015-04-30
JP2011126917A (ja) 2011-06-30
US20110086040A1 (en) 2011-04-14
CN103977403A (zh) 2014-08-13
IL240410A0 (en) 2015-09-24
AU2005209854B2 (en) 2011-01-20
EP2910253A1 (en) 2015-08-26

Similar Documents

Publication Publication Date Title
DK1720571T3 (da) Fremgangsmåde til behandling af hæmolytisk sygdom
IL284991A (en) Antibodies against cd38 for treatment of multiple myeloma
DK1828164T3 (da) Fremgangsmåde til fremstilling af N-phenylpyrazol-1-carboxamider
DK1778668T3 (da) Fremgangsmåde til fremstilling af dihydropteridion
DK1893586T3 (da) Fremgangsmåde til fremstilling af 1-alkyl-3-phenyluraciler
DK1716162T3 (da) Phosphonater, amidomonophosphonater, amidobisphosphonater til behandling af virussygdomme
DK1706112T3 (da) Fremgangsmåder til at behandle en inflammatorisk-beslægtet sygdom
DK1701941T3 (da) Forbindelser til behandling af sygdomme med celleproliferation
DE602005015234D1 (de) Zusammensetzungen zur wäschebehandlung
DE602005014252D1 (de) Zusammensetzungen zur wäschebehandlung
DK1748077T3 (da) Fremgangsmåde til fremstilling af protein
DE602005010597D1 (de) Bildaufzeichnungsverfahren
DK1611108T3 (da) Fremgangsmåde til fremstilling af telmisartan
DK1708992T3 (da) Sulfonamidderivater til behandling af sygdomme
NO20076030L (no) Fremgangsmåte for fremstilling av hydroklorsilaner
DK1813678T3 (da) Fremgangsmåde til fremstilling af glycogen
DK1756049T3 (da) Fremgangsmåde til fremstilling af 1,4-diphenylazetidinon-derivater
DK1678135T3 (da) Fremgangsm de til fremstilling af n-amino-substituerede hetorocykliske forbindelser
DK1687297T3 (da) Triazindimerer til behandling af autoimmunsygdomme
EP1765735A4 (en) SLUDGE TREATMENT PROCESS
DK1831223T3 (da) Fremgangsmåde til fremstilling af L-biopterin
DK3332789T3 (da) Cladribinkur til behandling af multipel sklerose
DK1881830T3 (da) 4-phenyl-5-oxo-1,4,5,6,7,8-hexahydroquinolin-derivater til behandling af infertilitet
DK1814555T3 (da) S-mirtazapin til behandling af hedeture
DK1805316T3 (da) Fremgangsmåde til fremstilling af de enantiomere former af cis-3-hydroxycy-